The health ministry on Friday warned that the breast cancer drug Verzenio is now suspected of adversely affecting the lungs after 14 recipients in Japan developed a serious lung disease and three died.
The drug is suspected of causing the side effects in at least four of the 14 cases, including one fatality, the ministry said. Verzenio, developed by Eli Lilly and Co., received Japanese clearance in September last year and debuted in November.
The number of patients in Japan who have used the oral drug since its release is estimated at around 2,000, according to the Health, Labor and Welfare Ministry.
Verzenio is designed to block certain molecules involved in promoting the growth of cancer cells.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.